MX9705771A - Empleo de derivados de xantina para la modulacion de la apoptosis. - Google Patents

Empleo de derivados de xantina para la modulacion de la apoptosis.

Info

Publication number
MX9705771A
MX9705771A MX9705771D MX9705771D MX9705771A MX 9705771 A MX9705771 A MX 9705771A MX 9705771 D MX9705771 D MX 9705771D MX 9705771 D MX9705771 D MX 9705771D MX 9705771 A MX9705771 A MX 9705771A
Authority
MX
Mexico
Prior art keywords
modulation
formula
apoptosis
compound
preparation
Prior art date
Application number
MX9705771D
Other languages
English (en)
Spanish (es)
Inventor
Stefan Mullner
Claudia Dax
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19640556A external-priority patent/DE19640556A1/de
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of MX9705771A publication Critical patent/MX9705771A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX9705771D 1996-07-31 1997-07-30 Empleo de derivados de xantina para la modulacion de la apoptosis. MX9705771A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19630837 1996-07-31
DE19640556A DE19640556A1 (de) 1996-10-01 1996-10-01 Verwendung von Xanthinderivaten zur Modulation der Apoptose

Publications (1)

Publication Number Publication Date
MX9705771A true MX9705771A (es) 1998-08-30

Family

ID=26027961

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9705771D MX9705771A (es) 1996-07-31 1997-07-30 Empleo de derivados de xantina para la modulacion de la apoptosis.

Country Status (11)

Country Link
US (1) US5856330A (https=)
EP (1) EP0821960B1 (https=)
JP (1) JPH1067662A (https=)
AT (1) ATE236637T1 (https=)
AU (1) AU718237B2 (https=)
CA (1) CA2212205C (https=)
DE (1) DE59709755D1 (https=)
DK (1) DK0821960T3 (https=)
ES (1) ES2191794T3 (https=)
MX (1) MX9705771A (https=)
PT (1) PT821960E (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
DE19860802A1 (de) * 1998-12-30 2000-10-26 Virgene Pharmaceuticals Ag Herstellung eines Mittels gegen Hepatitis B-, HI-, Paramyxo und Orthomyxo-Viren
US6458930B1 (en) 2000-11-28 2002-10-01 Cytokinetics, Inc. Aspergillus fumigatus cofilin
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
FR2825928B1 (fr) * 2001-06-18 2004-04-02 Ecole Norm Superieure Cachan Composition pharmaceutique pour le diagnostic, la prevention ou le traitement d'une pathologie tumorale, comprenant un agent modulateur de l'etat polymerisation de l'actine
EP1459758B1 (en) 2001-12-28 2009-02-25 Asubio Pharma Co., Ltd. Cofilin for promoting the proliferation and/or differentiation of hematopoietic stem cells and/or hematopoietic precursor cells
DE10217254A1 (de) * 2002-04-15 2003-10-23 Proteosys Ag Verwendung von Substanzen zur Behandlung von Tumoren
GB0224014D0 (en) * 2002-10-15 2002-11-27 Oxford Glycosciences Uk Ltd A protein involved in therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3737433A (en) * 1964-09-05 1973-06-05 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines
DE2335170C2 (de) * 1973-07-11 1989-07-20 Hoechst Ag, 6230 Frankfurt 1,3-Dialkyl-7-(hydroxyalkyl)-xanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE3508097A1 (de) * 1984-07-21 1986-02-06 Hoechst Ag, 6230 Frankfurt Kombinationspraeparat aus xanthinderivaten und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
IL100535A (en) * 1986-12-31 1994-05-30 Hoechst Roussel Pharma Pharmaceutical preparations containing a history of xanthine to relieve disease states
IL99811A (en) * 1990-10-30 1996-03-31 Roussel Uclaf 3-cycloalkyl-propanamides their tautomer forms and their salts preparation process and compositions containing them
WO1992007566A2 (en) * 1990-11-01 1992-05-14 Board Of Regents, The University Of Texas System Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues
ES2093138T3 (es) * 1991-05-23 1996-12-16 Hoechst Ag El empleo de 1-(5-oxohexil)-3-metil-7-n-propil-xantina en cirugia vascular.
WO1992021344A2 (en) * 1991-05-24 1992-12-10 Fred Hutchinson Cancer Research Center Modulation of cellular response to external stimuli
MX9203323A (es) * 1991-07-11 1994-07-29 Hoechst Ag El empleo de derivados de xantina para el tratamiento de lesiones secundarias de las celulas nerviosas y trastornos funcionales despues de traumas craneo-cerebrales.
TW209834B (https=) * 1991-12-11 1993-07-21 Hoechst Ag
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
ATE146078T1 (de) * 1992-02-22 1996-12-15 Hoechst Ag Verwendung von xanthinderivaten zur behandlung von muskelschädigungen nach vollständiger unterbrechung der blutzirkulation
US5763446A (en) * 1992-03-26 1998-06-09 University Of Southern California Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases
GB9321083D0 (en) * 1993-10-13 1993-12-01 Univ Mcgill Phosphatase inhibitors in channel diseases
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
AU3539795A (en) * 1994-08-25 1996-03-14 Medical University Of South Carolina Methods of treating cold symptoms using pentoxifylline
DE69534438T2 (de) * 1994-12-29 2006-06-29 The Regents Of The University Of California, Oakland Verbindungen für Ceramid-vermittelter Signalübertragung

Also Published As

Publication number Publication date
AU718237B2 (en) 2000-04-13
CA2212205C (en) 2007-12-04
CA2212205A1 (en) 1998-01-31
AU3236797A (en) 1998-02-05
EP0821960B1 (de) 2003-04-09
DE59709755D1 (de) 2003-05-15
ATE236637T1 (de) 2003-04-15
DK0821960T3 (da) 2003-07-21
JPH1067662A (ja) 1998-03-10
PT821960E (pt) 2003-08-29
ES2191794T3 (es) 2003-09-16
US5856330A (en) 1999-01-05
EP0821960A1 (de) 1998-02-04

Similar Documents

Publication Publication Date Title
MY119150A (en) Azetidine derivatives, their preparation and medicaments containing them
WO1996032003A3 (en) Tetrahydroimidazopyridoindolediones and their use as medicaments
AU4419193A (en) Synthesis of 1,4,7-triazacyclononane derivatives
AU8266491A (en) Serotonin 5HT1A agonists
ES2187660T3 (es) Derivados de rapamicina.
AU6017296A (en) Isocoumarin derivatives and use thereof in drugs
EP0781561A4 (en) NEW MEDICAL USE OF A 5HT 3 ANTAGONIST?
AU3744397A (en) Total synthesis of antitumor acylfulvenes
MX9705771A (es) Empleo de derivados de xantina para la modulacion de la apoptosis.
GR3031781T3 (en) Antifungal sordaridin derivatives
GR3029847T3 (en) Benzothiadiazine derivative process for its preparation and pharmaceutical compositions containing it
NZ325235A (en) New phenylamidine derivatives, a process for preparing the same and their use as medicaments
GR3031335T3 (en) Cck or gastrin modulating 5-heterocyclic-1,5-benzodiazepines
MX9805023A (es) Derivados de 1-metilcarbapenem.
MX9700807A (es) Derivados de 3-azabiciclo (3.2.0)heptano n-sustituidos utiles como neurolepticos.
NZ309765A (en) substituted 4-carboxamido-6-(N-arylsulphonylamido)-benzopyran derivatives and medicaments
AU1183783A (en) Pyriod (3,4-c),psoralens
AU6063498A (en) Alkylenediamine derivative, anti-ulcer drug, and antibacterial drug
AU4361996A (en) The use of inositoltrisphosphate for the preparing of medicaments
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
AU2207688A (en) Anxiolytically active piperazine derivatives
AU7718796A (en) 4-hydroxycoumarin-3-carboxamides for the treatment of diabetes mellitus
AU664101B2 (en) Novel phospholipid derivatives
IL136181A0 (en) 5H-PYRANO[2,3-d:6,5-d'] DIPYRIMIDINE DERIVATIVES HAVING AN ANTIBACTERIAL, ANTIVIRAL, AND IMMUNO-MODULATING ACTIVITY
HU9904686D0 (en) New hydroxy-bicyclolactam derivatives, their use and medicaments containing them

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees